Clinical pharmacologists and toxicologists are often faced with predicting equivalent dosages for humans from biological observations in laboratory animals. Allometric scaling has been used extensively as the basis for extrapolation of drug dosage that might be expected to produce the equivalent biological effects. Allometry is the study of size and its consequences and it is based on the anatomical, physiological, and biochemical similarities between animals. In this review, retrospective analyses have been performed based on data reported in the literature in an attempt to determine the utility of allometric scaling for human dose projections from pre-clinical data for compounds that are delivered by inhalation. The limited pre-clinical efficacy data available on inhaled drugs that are also used clinically supports the current method of scaling using a fixed allometric exponent of 0.67. An example of the utility of the human inhaled dose projections for planning inhaled toxicology studies is also presented.
Introduction
There are many advantages to inhaled administration of drugs for the treatment of respiratory diseases. Inhaled delivery applies the therapeutic agent directly to the site of action; the lungs. A high local concentration of the drug in the lungs offers a significant advantage that minimizes dose and systemic exposure, and maximizes efficacy. This is an important advantage that can greatly increase the therapeutic index (TI). The TI is the ratio of dose of drug that causes a side-effect over the dose of drug that provides efficacy.
As new drugs delivered by the inhaled route are developed, it is essential to appropriately translate the efficacious drug dose from preclinical efficacy studies to predict an efficacious human dose for clinical trials. An estimate of the effective human inhaled dose deposited in the lungs also helps to plan the delivered doses used in inhalation toxicology studies required for clinical trials (Degeorge et al., 1997) . It is common to use an allometric approach to predict human drug doses from pre-clinical efficacy studies (Boxenbaum & DiLea, 1995) . Allometry is the study of size and its consequences (Gould, 1966) , and it is based Pharmacology & Therapeutics 178 (2017) [141] [142] [143] [144] [145] [146] [147] Abbreviations: TI, therapeutic index; LABA, long acting beta agonist; LAMA, long acting muscarinic antagonist. 
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Pharmacology & Therapeutics j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / p h a r m t h e r a on the assumption that there are anatomical, physiological, and biochemical similarities between animals (Mahmood, 1999) . Fig. 1 demonstrates how the allometric scaling concept applies to interspecies scaling for a few physiological parameters, and that these parameters scale with different allometric exponents. Herein an allometric scaling exponent is retrospectively calculated from experimental rodent efficacy data and the known inhaled clinical dose that needs to be deposited in the human lung. This is done for four inhaled compounds currently used clinically; the inhaled corticosteroids mometasone and budesonide, the β-agonist bronchodilator salbutamol, and the anticholinergic bronchodilator ipratropium. This review attempts to determine the utility of an allometric scaling approach to allow interspecies correlation of inhaled drug dose, a pharmacologic parameter. The limited pre-clinical efficacy data available on inhaled drugs that are also used clinically supports the current method of scaling using a fixed allometric exponent of 0.67 (FDA, 2015) . It must be remembered that any allometric approach is empirical and is but a simple and useful correlation (Boxenbaum & DiLea, 1995) . One must also keep in mind that the dose predicted by these scaling methods cannot be used in clinical trials without supporting pre-clinical toxicology studies with appropriate safety margins above the predicted efficacious dose (Degeorge et al., 1997; Forbes et al., 2011) . Therefore, an example of the process of how the human dose projections are used to plan the pre-clinical inhaled toxicology studies is presented.
Aerosol dose definitions
There are many ways in which the dose can be expressed for drugs delivered by inhalation. This can lead to confusion when comparing results from studies performed in different laboratories. Recently, it was recommended that delivered dose and deposited dose be adopted as the standard terminology (Alexander et al., 2008; Forbes et al., 2011) . The delivered dose is the amount of drug inhaled by the animal and the deposited dose is the amount of drug deposited in the lungs. In general, an "inhaled dose" to a toxicologist is a delivered dose and an "inhaled dose" to a pharmacologist is a deposited dose. It is therefore important to clarify if the "inhaled dose" is a delivered or deposited dose. The delivered dose differs from the dose generated by the inhalation device (or metered dose) by an amount that is retained by the inhalation device (some of the drug aerosol particles stick to the walls of the device). The delivered dose differs from the deposited dose (or dose deposited in the lungs) by the pulmonary deposition fraction or the amount of aerosol that can make it into the lungs (i.e. does not get stuck in the back of the mouth, or in the nose if delivered by noseonly inhalation). To convert the delivered dose to the deposited dose, one must know the pulmonary deposition fraction (Alexander et al., 2008; Forbes et al., 2011) . Airway geometry makes the pulmonary deposition fraction not only species dependent, but also highly dependent on the particle size distribution of the aerosol (Scheuch & Siekmeier, 2007) . Throughout this manuscript we will assume for simplicity in all rodent, canine, nonhuman primate, and human dose calculations, the pulmonary deposition fractions are 10%, 25%, 30%, and 40% (Snipes, McClellan, Mauderly, & Wolff, 1989) , respectively. These pulmonary deposition fraction values do not necessarily reflect the actual pulmonary deposition fraction of pharmaceutical aerosols. The inherent limitations associated with using these pulmonary deposition fraction values has been reviewed at length (Forbes et al., 2011) . These pulmonary deposition fraction values should be replaced with more accurate values based on the animal species and the experimentally measured aerosol particle size distribution for the drug, if available (Olsson, Borgstrom, Lundback, & Svensson, 2013) .
Pre-clinical studies for inhaled drugs
Pre-clinically, inhaled compounds are optimized to increase the TI which requires in vivo efficacy and side effect measurements. Initially, these measurements can be made in separate assays. Usually the drug is delivered topically to the lungs for the efficacy measurement and systemically for the side-effect measurement. Final determination of a TI for an inhaled drug, where efficacy and side effect are measured in the same animals after inhaled administration, requires dose/response studies that achieve exposure at least 10 times greater than the efficacious dose deposited in the lungs. At these supramaximal efficacious levels, either a measureable side effect is induced or the targeted safety margin (TI N 10) is confirmed.
Conformation of an appropriate safety margin enables inhaled toxicology studies. The outcome of the toxicology studies will be used to set the maximum dose allowed in clinical trials. The inhaled human deposited efficacious dose projected from the pre-clinical efficacy studies reassures that the maximum dose allowed in the clinical trials by the toxicology studies is not a sub-efficacious dose. A TI calculated from animals dosed by inhalation derisks the toxicology studies, but it is not Fig. 1 . Allometric plots for the physiological parameters body surface area, lung mass, and lung surface area scale log-linearly with body mass. Power function curve fits for each parameter in lower right hand corner of each graph. Data from (Chappell & Mordenti, 1991) , (Snipes, 1989) , and (Gehr et al., 1981) . required in order to proceed with toxicology studies. Safety margins are often estimated in separate assays as discussed earlier.
It is often asked, why perform the relatively complicated pre-clinical aerosol inhalation efficacy studies when it is easier to deliver the drug by direct instillation into the lung? The short answer is; drugs can be much more potent when delivered by aerosol inhalation than direct instillation due to the non-uniform distribution in the lung using direct instillation (Cooper, Ferguson, & Grime, 2012 ). The only current way to uniformly deliver large doses of drug to the lungs of animals is by aerosol inhalation.
Aerosol delivery vs direct instillation into the lung
The nose-only aerosol inhalation technique for rodents currently requires hundreds of milligrams of micronized drug to create a high quality aerosol with a large inhalable fraction to achieve a uniform pulmonary distribution. Nose-only inhalation is the only inhaled drug delivery technique that provides a uniform drug distribution throughout the lungs (Brain, Knudson, Sorokin, & Davis, 1976; Cooper et al., 2012; Leong, Coombs, Sabaitis, Rop, & Aaron, 1998; Liu, Li, Pauluhn, Trubel, & Wang, 2013; Zecchi et al., 2013) . Uniform drug distribution in the lung is possible with nose-only inhalation as a high quality respirable aerosol is generated and maintained for a period long enough to allow the animals to inhale an efficacious deposited dose (Alexander et al., 2008) . The deposited dose can be utilized as the denominator to calculate a TI (Biju et al., 2011) , ensuring that the drug has an appropriate exposure multiple (usually N10 for rodents (Degeorge et al., 1997) ) present to mitigate the potential risk of manifestation of any systemic side effects. It is also useful when planning inhaled toxicology studies and clinical trials. When combined with animal disease models and pharmacodynamic measurements, nose-only inhalation dosing not only provides information on the efficacious deposited dose, but also the duration of action required to maintain the targeted efficacy; both helpful for dose translation to humans.
Direct instillation delivery methods are an option when the amount of drug is limited, usually due to cost associated with chemical synthesis. All direct instillation delivery methods will suffer from non-homogeneous pulmonary deposition, with more drug concentrated along the central airways and less well represented in the parenchymal/alveolar regions (Cooper et al., 2012; Leong et al., 1998; Zecchi et al., 2013) . Therefore, caution should be used when scaling doses from data generated by direct instillation methods, as drugs tend to be more potent when delivered by aerosol inhalation compared to direct instillation methods (Cooper et al., 2012) . Direct instillation methods including: intranasal (Siddiqui et al., 2008) or intratracheal liquid (Brain et al., 1976; Liu et al., 2013) and spray instillation (Bivas-Benita, Zwier, Junginger, & Borchard, 2005) or dry-powder insufflation (Guillon et al., 2012; Morello et al., 2009 ); can be used as a screening tool to determine the approximate dose range for later inhalation studies, or to determine the ranking of efficacy/toxicity for a series of structurally similar drugs (Pauluhn & Mohr, 2000) . Efficacy data generated by direct instillation methods complements inhaled aerosol approaches as it provides an opportunity to demonstrate efficacy with a few milligrams of compound and without specialized aerosol generation equipment.
The fundamental requirement in a pharmacodynamic study is that the dose delivered be known. In inhalation pharmacology, due to difficulties in measuring the actual inhaled dose that deposited in the lungs, deposited doses must be estimated using mathematical relationships in order to interpret experimental results. During a typical preclinical inhalation drug efficacy experiment, the aerosol particle size and concentration are measured (Oldham, Phalen, & Budiman, 2009) and these values are used to calculate the delivered dose, pulmonary deposition fraction, and deposited dose (Alexander et al., 2008; Forbes et al., 2011) .
Allometric scaling of drug dose

Introduction to allometric scaling
The infamous death of Tusko the elephant (West, Pierce, & Thomas, 1962) is commonly cited in the literature to remind us that drug doses should not be extrapolated on the basis of a simple comparison of body masses. One reason for this is that larger animals have slower metabolism of drugs which likely lead to the overdosage of Tusko (Harwood, 1963) . Extrapolating animal data to humans by allometric scaling is based on the observation that many diverse anatomical, biochemical, pharmacokinetic, and physiological parameters correlate as a power-law function of body mass (Adolph, 1949) . The power-law equation (Eq. (1)) yields
linear plots as the body mass (M) from multiple species is plotted against a parameter of interest (Y) on a log-log scale (Fig. 1) . The allometric coefficient (a) represents the value of the parameter of interest for a 1 kg animal and the allometric exponent (b) is an interspecies scaling factor which relates the body mass to the parameter of interest. When a parameter scales log-linearly with body mass for multiple species, the allometric approach may be useful to extrapolate non-human animal data to predict the value of the parameter of interest (in our case drug dose) in humans. The power-law function turns into a linear function after logarithmic transformation (Eq. (2)), so that estimates of the intercept (log(a)) and slope (b) can be computed by linear regression.
Dose scaling for systemically delivered drugs
The idea of using allometric scaling to estimate a human dose from pre-clinical pharmacology data for drugs delivered by inhalation comes from the common use of allometric dose scaling for systemically administered drugs. Human dose estimation from pre-clinical pharmacology data for systemically administered drugs is based on the normalization of doses to body surface area (FDA, 2015) . Fixed exponent body surface area allometric scaling (b = 0.67, Fig. 1 ) is the standard way to approximate equivalent interspecies doses unless extrapolating doses based on other parameters is known to be more appropriate.
Why would dose scale with the same allometric coefficient as body surface area? A possible explanation is that human doses are dependent on many factors (physicochemical properties, pharmacokinetics, active metabolites, etc.) however dose can sometimes be correlated with only one variable. Commonly that variable is the removal of drug from a fixed volume of blood per unit time (Davidson, Parker, & Beliles, 1986) . Clearance (a pharmacokinetic parameter) for some drugs is dependent on metabolic rate. Metabolic rate and body surface area scale with the same allometric exponent (Davidson et al., 1986; Mahmood & Balian, 1999) . Subsequently, large animals have a lower metabolic rate due to their minimal requirement compared to small animals to generate heat by metabolism to maintain their body temperature. This is due to their smaller body surface area to mass ratio (Chappell & Mordenti, 1991; Kleiber, 1947) .
Pharmacokinetic parameters like clearance can control the concentration of drug in the body and therefore the dose required. This line of reasoning suggests that the link between drug dose and body surface area relies on drug clearance and metabolic rate; and all of these parameters could scale with the same allometric exponent. Therefore, it is possible to consider scaling drug dose for systemically delivered drugs across species based on an allometric equation with b = 0.67. The fact that some drug doses can scale proportional to body surface area or metabolism (Boxenbaum & DiLea, 1995; Chappell & Mordenti, 1991; Davidson et al., 1986) does not imply that body surface area or metabolic rate are determinants of the required efficacious drug dose; it simply correlates.
Assuming that drug dose per unit body mass (i.e. μg/kg) scales loglinearly with body mass according to a power-law function enables the allometric approach to extrapolate non-human animal data to predict the human dose using Eq. (10) (derived in the Appendix). In Eq. (10): X h is the human drug dose normalized to body mass (μg/kg), M h is the human body mass (kg), X a is the animal drug dose per unit body mass (μg/kg), M a is the animal body mass (kg), and b is the allometric exponent.
Dose scaling for inhaled drugs
Unlike the data for systemically delivered drugs described above, scientific literature to support the assumption that allometric scaling is useful to predict the dose of a drug delivered by inhalation is lacking. Nonetheless, Eq. (10) can be used to calculate a predicted human effective dose using a known effective dose and body mass of a non-human animal, human body mass, and the appropriate allometric exponent. The exponent used ideally should be empirically determined individually for each drug using data from multiple animal species. Unfortunately, to my knowledge, this has never been done for any inhaled drug. This is due to the difficulty of developing a similar animal disease model in multiple species and the different methods required to deliver aerosols to different species. Using a single species is pragmatic and may lead to incorrect estimation of the drug dose due to body mass independent differences between the species used and humans. An example of a body mass independent source of interspecies variability is differences in cytochrome P450 isoenzymes which affect drug metabolism (Riviere, Martin-Jimenez, Sundlof, & Craigmill, 1997) . Single species retrospective human effective dose allometric analysis is performed in the next section. This is due to the lack of pre-clinical deposited inhaled efficacious dose data in multiples species for a drug that also has complimentary human inhaled effective dose data.
Inhaled pulmonary deposited dose translation: Retrospective analysis
The motivation behind this retrospective analysis is to determine the validity of using allometry with a fixed exponent of 0.67, as is currently done with systemically delivered drugs, to scale doses of inhaled drugs. The line of reasoning describe above that links drug clearance/metabolism, to metabolic rate, to body surface area (b = 0.67), could apply to inhaled drug dose. An equally valid line of reasoning might correlate inhaled drug dose scaling to lung mass or lung surface area, which have the allometric exponents shown in Fig. 1 of 1.1 and 0 .9, respectively. To retrospectively determine applicable allometric exponents for inhaled dose scaling, inhaled rodent efficacy data from inhaled compounds that are currently used clinically were used as input to Eq. (10). The allometric exponent required to predict the known clinically effective deposited dose was backcalculated. The rodent effective deposited doses and clinically effective deposited doses for salbutamol, budesonide, ipratropium, and mometasone, are summarized in Table 1 . Utilizing Eq. (10) with a mouse body mass of 0.03 kg, a rat body mass of 0.25 kg, and a human body mass of 60 kg; the allometric exponents that would allow the clinical inhaled deposited dose to be calculated from the rodent efficacy data are 0.44, 0.60, 0.95, and 0.78; respectively. Albeit inappropriate to draw firm conclusions from such a small dataset (n = 4), the average of these allometric exponents is 0.69, which supports the current method of scaling using a fixed allometric exponent of 0.67. The observation that all the exponents are less than one supports the fact that equivalent efficacious doses should be smaller (on a body mass (μg/kg) basis) in larger animals. This reinforces the utility of fixed exponent allometric scaling with an exponent less than one for interspecies inhaled dose scaling.
Inhaled delivered dose: toxicology study design
The most obvious need for human dose projections is for planning clinical trials to include what should be an efficacious dose. As mentioned above, the doses in clinical trials are capped by supporting toxicology studies. The question of how to plan the toxicology studies to ensure the predicted human effective dose can be tested in the clinical trial is not simple to answer and should be planned by an inhalation toxicologist. To partially outline the process, one potential scenario to calculate targeted toxicology study delivered doses is outlined in Fig. 2 . It uses allometric scaling (b = 0.67) of the efficacious pre-clinical deposited dose and recommended literature safety margins (Degeorge et al., 1997) and pulmonary deposition fractions for the species tested in the inhaled toxicology studies to calculate targeted delivered doses for toxicology studies. The graphs in Fig. 3 use the scenario outlined in Fig. 2 and standard values for body masses to enable quick estimates of the projected efficacious human delivered dose from the experimentally determined efficacious deposited dose (top graph) and the target toxicology delivered dose from the projected efficacious human delivered dose (bottom graph) for multiple species. These graphs are helpful for rough compound requirement projections needed for the toxicology studies.
Conclusions
The potential utility of allometric scaling to provide an initial estimate for a human deposited efficacious dose of a novel inhaled drug has been demonstrated. It illustrates the relevance of pharmacodynamic studies conducted in animals where the drug is delivered by inhalation. The complexity of the pharmacokinetic and pharmacodynamic responses to inhaled drugs decreases the probability that there is one common extrapolation base (M 0.67 ). Therefore, the exponent for inhaled dose allometric scaling should be empirically determined for each compound, preferably in multiple species. This is rarely done due to the difficulty of developing a similar animal disease model in multiple species and the different methods required to deliver aerosols to different species. Further complicating matters, we have also recently shown that the allometric exponent can depend on the biologic function (efficacy endpoint) measured. In pre-clinical respiratory disease models, improvements in lung function may require higher doses than to decrease pulmonary inflammation (Phillips et al., 2016) . This suggests (Stevenson, Sridhar, & Phillips, 2013) . The utility of allometic scaling for interspecies inhaled dose extrapolations mainly comes from the requirement for only 4 input values (an efficacious deposited dose for the pre-clinical species, body masses for both species, and the allometric scaling coefficient) to calculate an estimated effective deposited dose for humans. This utility is somewhat offset by the significant intrinsic limitations of allometric dose scaling (Boxenbaum & DiLea, 1995) . Also the experiments used to obtain the efficacious deposited dose for the pre-clinical species often contain many assumptions that could be improved (i.e. minute ventilation rate during aerosol inhalation is calculated and not measured, deposition fraction is calculated assuming the aerosol is monodisperse). Despite these limitations, allometric scaling does have a place in the drug development decision making process. A better understanding of the mechanisms and assumptions which are used to calculate the estimate of the effective dose delivered to the lung that is used as input to the allometric scaling equation may improve the predictive nature of allometry, but does not make the allometric scaling method "mechanistic". Allometric scaling of lung deposited dose is empirical and the exponent used has no physiological meaning. Therefore, addition of mechanistic "correction factors", like a factor to account for the difference in the nose-only aerosol delivery used pre-clinically versus oral inhalation with an inhaler that is used in the clinic, are unnecessary as they are already part of the assumptions that went into the calculation of the pre-clinical and clinical efficacious deposited doses.
The utility of allometric scaling to extrapolate duration of action (a pharmacokinetic endpoint) of inhaled drugs should also be explored as biological time measured in heartbeats scales with the allometric exponent 0.25 (Mordenti, 1986) and may suggest that a duration of action in chronological time of 3.6 h in mice (calculated using Appendix Eq. (6)) would represent 24 h of efficacy (or q.d. dosing) in humans. This hypothesis could be tested with the recently approved long acting beta agonist (LABA) or long acting muscarinic antagonist (LAMA) drugs (Spina, 2014) and would provide pre-clinical drug development a duration of action goal when optimizing the properties of novel inhaled drugs.
The limited pre-clinical efficacy data available in the literature on inhaled drugs that are also used clinically supports the current method of scaling using a fixed allometric exponent of 0.67 (FDA, 2015) . The utility of fixed exponent (b = 0.67) allometric scaling from a single species to project an inhaled efficacious human dose is pragmatic but should be Multiply by 4 (25% deposition) Target delivered dose in rat toxicology study Target delivered dose in canine toxicology study Fig. 2 . Flow chart for estimating the human delivered dose and rat/canine target delivered doses for toxicology studies using an experimentally determined efficacious deposited dose from a pre-clinical animal efficacy study. The delivered dose is the amount of drug inhaled by the subject and the deposited dose is the amount of drug calculated to be deposited in the lungs.
used cautiously. The limited number of marketed inhaled drugs, combined with the limited number of pre-clinical datasets with pharmacodynamic endpoints for drugs delivered by inhalation precludes a more detailed assessment of the utility for fixed exponent allometric scaling for inhaled dose extrapolation. Fig. 3 . Diagrams to allow a graphical approximation of projected efficacious human delivered dose from a pre-clinical experimentally determined efficacious deposited dose (upper panel) and an approximation of target delivered doses for rat and canine toxicology studies from the projected efficacious human delivered dose (lower panel). These diagrams can be used in conjunction with experimentally determined pre-clinical efficacious deposited doses from mouse, rat, nonhuman primate or canine studies. Assumptions: mouse body mass 0.03 kg, rat body mass, 0.25 kg, nonhuman primate body mass 2.4 kg, canine body mass 10 kg, human body mass 60 kg, allometric scaling coefficient b = 0.67, 10% deposition rat, 25% deposition canine, 40% deposition human, 6× safety margin canine, 10× safety margin rat.
